<DOC>
	<DOCNO>NCT00382863</DOCNO>
	<brief_summary>The purpose study determine patient HeartNet Ventricular Support System optimal medical device therapy arm ( Treatment group ) show statistically significant improvement compare patient optimal medical device therapy alone arm ( Control group ) 6 month follow-up .</brief_summary>
	<brief_title>Prospective Evaluation Elastic Restraint LESSen Effects Heart Failure ( PEERLESS-HF ) Trial</brief_title>
	<detailed_description>In United States alone , five million people suffer heart failure ( CHF ) estimate 400,000 700,000 new case diagnose year . Caused variety cardiac condition , systolic heart failire ( HF ) end-stage heart disease heart fail pump . Once diagnosed disease , le 50 % patient live five year , less 25 % survive ten year . The number death United States condition double since 1979 , average 250,000 annually . Paracor Medical , Inc. develop elastic prosthetic wrap design apply gentle mechanical support fail heart . The Implant compliant elastic structure design conform epicardial surface right leave ventricle . It support heart throughout cardiac cycle design offload ventricle reduce wall stress . The objective clinical trial evaluate safety efficacy HeartNet Ventricular Support System optimal medical device therapy ( Treatment group ) compare optimal medical device therapy ( i.e. , medication , cardiac resynchronisation therapy , pacemaker ) alone ( Control group ) treatments patient heart failure . Efficacy HeartNet Ventricular Support System Treatment group compare optimal medical device therapy Control group evaluate base upon cardiopulmonary test ( Peak VO2 ) , six ( 6 ) minute walk distance quality life assessment , measure Minnesota Living Heart Failure ( MLWHF ) questionnaire . Safety HeartNet Ventricular Support System Treatment group compare Control group evaluate base all-cause mortality rate . Paracor Medical intend submit data obtain clinical trial support Pre-Market Approval Application United States Food Drug Administration .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Symptomatic heart failure enrollment ( American College Cardiology [ ACC ] /American Heart Association [ AHA ] Stage C ) due ischemic nonischemic dilate cardiomyopathy 2 . On stable , evidencebased medical device therapy heart failure 3 month prior randomization &lt; &gt; Pharmacological Therapy ( appropriate ) &lt; &gt; angiotensin convert enzyme ( ACE ) inhibitor angiotensin II receptor blocker ( ARB ) patient ACE inhibitor intolerance nitrate/hydralazine investigator discretion &lt; ii &gt; beta blocker &lt; iii &gt; diuretic , aldosterone inhibitor &lt; b &gt; Ejection fraction &lt; = 35 % maintain optimal medical therapy &lt; c &gt; Cardiac Resynchronization Therapy ( CRT ) , Cardiac Resynchronization TherapyDefibrillator ( CRTD ) &lt; &gt; If implant CRT CRTD , must implant &gt; = 3 month randomization &lt; ii &gt; If currently eligible anticipate eligibility CRT CRTD within 6 month , patient enrol study Specific Qualifying Characteristics 1 . Six ( 6 ) minute walk 150 450m 2 . Peak VO2 male : 10.020.0 ml/kg/min ; Peak VO2 female : 9.018.0 ml/kg/min 3 . Left ventricular end diastolic diameter ( LVEDD ) &lt; 85mm index &lt; 40mm/m2 ( LVEDD/BSA ) 4 . Heart failure duration &gt; = 6 month Patient History 1 . Heart failure due reversible condition 2 . Hypertrophic obstructive cardiomyopathy ( HOCM ) 3 . Left ventricular assist device ( LVAD ) , intraaortic balloon pump ( IABP ) intravenous inotropes require patient end stage heart failure despite maintenance best medical therapy 4 . Myxoma 5 . Active infection , sepsis , endocarditis , myocarditis pericarditis 6 . Myocardial infarction , stroke , transient ischemic attack , cardiac major surgery , implantable cardioverter defibrillator ( ICD ) pacemaker implantation 3 month prior entry 7 . Positive pregnancy test premenopausal female 8 . Less 18 year &gt; = 75 year old 9 . Hemoglobin level le 10 gm/dL creatinine &gt; 2.5 mg/dL 10 . Uncontrolled medical condition increase surgical risk 11 . Comorbid condition investigator 's opinion reduce life expectancy le 2 year Surgical Anatomical Considerations 1 . Heart measurement large small Implant size 2 . Restrictive cardiomyopathy 3 . Not candidate sternotomy standard thoracotomy surgical approach 4 . Expected adhesion previous surgical procedure 5 . History constrictive pericarditis 6 . Previously place coronary artery bypass graft ( CABG ) anticipate need coronary artery bypass graft 7 . Not candidate cardiopulmonary bypass 8 . Anatomical mitral valve regurgitation 2+ great time enrollment 9 . Pulmonary function test follow result : Forced expiratory volume ( FEV1 ) &lt; 1L FEV1 1 3L , force expiratory volume divide forced vital capacity ( FEV1/FVC ) &lt; 60 % 10 . Cardiac thoracic condition might require operative correction . Cardiac transplantation include exclusion criterion . 11 . Other elective surgical procedure time index hospitalization within 30 day , whichever long Other 1 . Any medical condition , judgment investigator , make patient poor candidate procedure 2 . Currently enrol participate last 30 day another therapeutic interventional clinical study 3 . Unwilling/unable comply followup 4 . Unwilling/unable give sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>heart failure</keyword>
	<keyword>cardiac support</keyword>
	<keyword>Paracor</keyword>
	<keyword>HeartNet</keyword>
	<keyword>PEERLESS-HF</keyword>
</DOC>